Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 12/20 | 1.00 |
| ▸ | RGS8 | P57771 | 11/20 | 1.00 |
| ▸ | GSK3B | P49841 | 7/20 | 0.82 |
| ▸ | GSK3A | P49840 | 3/20 | 0.82 |
| ▸ | PRKCA | P17252 | 2/20 | 0.70 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.60 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.60 |
| ▸ | RGS16 | O15492 | 1/20 | 0.53 |
| ▸ | RGS19 | P49795 | 1/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13517889 | 0.94 | RGS4 (0.88) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL2107216 | 0.91 | GSK3B (1.00) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL13517418 | 0.88 | RGS4 (0.78) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL13516932 | 0.87 | RGS4 (1.00) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL29239064 | 0.84 | RGS4 (0.75) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL13517354 | 0.84 | RGS4 (0.74) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL2106404 | 0.84 | GSK3B (0.75) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL13516844 | 0.83 | RGS4 (0.73) | RGS4RGS8GSK3BGSK3APRKCA | |
| SCHEMBL15212631 | 0.83 | GSK3B (0.78) | RGS4RGS8GSK3BGSK3APRKCA | |
| Krm-7777 SCHEMBL3384141 | 0.83 | GSK3B (1.00) | RGS4RGS8GSK3BGSK3APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4340832-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Amo Pharma Ltd. (GB) | 2024-03-27 | — | — | EP | claimed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | claimed |
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-12-08 | — | — | US | claimed |
| EP-4094760-A1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Consejo Superior De Investigaciones Científicas (ES) | 2022-11-30 | — | — | EP | claimed |
| WO-2022243973-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-11-24 | — | — | WO | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| EP-4340832-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | Amo Pharma Ltd. (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-12-08 | — | — | US | disclosed |
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | AMO PHARMA LTD. (GB) | 2022-12-08 | — | — | US | disclosed |
| EP-4094760-A1 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | Consejo Superior De Investigaciones Científicas (ES) | 2022-11-30 | — | — | EP | disclosed |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | NEUROPHARMA, S.A. (ES) | 2008-06-26 | — | — | US | disclosed |
| EP-1889619-A1 | USE OF THIADIAZOLIDINE-DERIVED COMPOUNDS AS NEUROGENIC AGENTS | Neuropharma, S.A. (ES) | 2008-02-20 | — | — | EP | disclosed |
| WO-2005097117-A1 | THIADIAZOLIDINONES AS GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097117-A1 | THIADIAZOLIDINONES AS GSK-3 INHIBITORS | NEUROPHARMA, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| EP-1586318-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A.U. (ES) | 2005-10-19 | — | — | EP | disclosed |
| EP-1586319-A1 | Thiadiazolidinones as GSK-3 inhibitors | Neuropharma S.A. (ES) | 2005-10-19 | — | — | EP | disclosed |
| US-20050222220-A1 | GSK-3 inhibitors | NEUROPHARMA, S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387399-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | RGS4 3507/4885RGS8 3197/4885GSK3B 3391/4885 |
| US-20050222220-A1 | GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | RGS4 4483/4885RGS8 4361/4885GSK3B 1/4885 |
| US-20080153886-A1 | Use Of Heterocyclic Compounds As Neurogenic Agents | GAP43, NGF, BDNF | RGS4 3784/4885RGS8 3843/4885GSK3B 848/4885 |
| US-20230241038-A1 | METHOD OF TREATING RNA REPEAT MEDIATED DISEASES WITH RNA REPEAT BINDING COMPOUND | TRDMT1, HNRNPDL, HNRNPD | RGS4 3507/4885RGS8 3197/4885GSK3B 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.